Boan Biotech today announced that patient enrollment has been completed for the Phase 3 clinical study (comparative clinical study of efficacy and safety) of BA9101 (Aflibercept Intravitreous Injectio...
Shanghai, February 23, 2023 - Luye Pharma Group today announced that it has received the approval by the competent authorities to initiate the first clinical trial in Europe for its Paliperidone Palmi...
Rykindo® is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma’s Central Nervous System (CNS) product portfolio to be marketed in the United State...
January 9, 2023 – Luye Pharma Group today announced the launch of the Named Patient Program (NPP) in Hong Kong, China, providing eligible local patients immediate access to the innovative anti-c...
January 09, 2023 - Luye Pharma Group announced today that BA1301 for injection, an innovative antibody-drug conjugate (ADC) candidate developed by its subsidiary Boan Biotech, has been approved for cl...
(30 December 2022, Hong Kong, China)Shandong Boan Biotechnology Co., Ltd. (“Boan Biotech” or the “Company”), a subsidiary of Luye Pharma Group, was officially listed on the Main Board of the Stock...
November 21, 2022 - Luye Pharma Group announced today that a pivotal study conducted in the U.S. for the company's in-house developed innovative formulation, Paliperidone Palmitate Extended-releas...
Luye Pharma Group today announced that Denosumab Injection (Boyoubei®) developed by its subsidiary Boan Biotech has been approved for launch in China by the National Medical Products Administration (N...
November 3, 2022 – Luye Pharma Group today announced that Ruoxinlin® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets), its innovative drug for treating Major Depressive Disorder (MDD)...
October 27, 2022 -- Luye Pharma Group announced today that BA2101 has been approved by the Center for Drug Evaluation of the National Medical Products Administration for clinical trials in China. This...